Home

News 335 views 1 comment

Study: Antibodies effective against bird flu

Monoclonal human antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, have been identified, reports Newswise.

Researchers at the Dana-Farber Cancer Institute, Burnham Institute for Medical Research, and the Centers for Disease Control and Prevention have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus.
These antibodies have the potential for use in combination with other treatments to prevent or treat certain types of avian flu.

Binding to the stem

The antibodies identified by the team of scientists neutralise a broad range of influenza A subtypes because they bind to the highly conserved stem region of H5 type hemagglutinin (HA). Binding to the stem prevents a conformational change in the protein that is necessary for viral entry into the host cell, thereby preventing further infection of host cells and the rise of escape mutants.

“The head portion of hemagglutinin is highly mutable, leading to the rise of forms of the virus that can evade neutralizing antibodies,” said Robert Liddington, Ph.D., professor and director, Infectious and Inflammatory Disease Center at Burnham and one of the investigators on the study. “However, the stem region of hemagglutinin is highly conserved because it undergoes a dramatic conformational change to allow entry of viral RNA into the host cell. It’s very difficult to get a mutation that doesn’t destroy that function, which explains why we aren’t seeing escape mutants and why these antibodies neutralize such a variety of strains of influenza.”

Costly but convenient

While more costly to produce than existing influenza drugs, therapeutic antibodies can be readily manufactured and stockpiled. In the event of a pandemic, the antibodies could be used in combination with antiviral therapies to contain the outbreak until a vaccine became available.

* The study was published online on February 22 in Nature Structural and Molecular Biology.

Source: Newswise Medical News

Related links:

Dana-Farber Cancer Institute

Burnham Institute for Medical Research

Centers for Disease Control and Prevention

Nature Structural and Molecular Biology

Natalie Berkhout

One comment

  • no-profile-image

    merve ocaktar

    The development of studies has been amazingly rapid...

Or register to be able to comment.